Related Experiment Video
Updated: Feb 27, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[State of the art: Direct oral anticoagulants and transfusion]
A-C Martin1, A Godier2, D M Smadja3
1Service de cardiologie, service de santé des armées, hôpital d'instruction des armées Percy, 92025 Clamart, France; Inserm UMR-S 1140, faculté de pharmacie, université Paris-Descartes, 75006 Paris, France.
Insights
Managing bleeding from direct oral anticoagulants (DOACs) is complex. While idarucizumab is available for dabigatran, reversing other DOACs and their associated bleeding remains a challenge.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Direct oral anticoagulants (DOACs) are widely used for stroke prevention in atrial fibrillation and venous thromboembolism.
- DOACs carry an inherent risk of bleeding, posing management challenges.
- Current therapeutic options for DOAC-induced bleeding are limited, with specific antidotes only available for dabigatran.
Purpose of the Study:
- To provide an updated overview of managing bleeding associated with direct oral anticoagulants.
- To integrate the role of idarucizumab, the specific antidote for dabigatran, into treatment strategies.
- To highlight the importance of measuring DOAC concentrations in managing bleeding events.
Main Methods:
- Review of current literature and clinical guidelines on DOAC-induced bleeding.
- Analysis of the role and efficacy of available and developing antidotes.
- Emphasis on the diagnostic value of DOAC concentration measurements.
Main Results:
- Idarucizumab is an established antidote for dabigatran-related bleeding.
- Antidotes for anti-factor Xa agents are still under development.
- The efficacy of prothrombin complex concentrates in reversing DOACs is uncertain.
- DOAC concentration measurement is crucial for guiding management decisions.
Conclusions:
- Effective management of DOAC-induced bleeding requires a strategic approach, considering available antidotes and diagnostic tools.
- Idarucizumab offers a specific reversal agent for dabigatran, simplifying its management.
- Further research and development are needed for effective reversal agents for other DOACs, with DOAC concentration monitoring playing a key role.
Abstract:
Direct oral anticoagulants (DOAC) are indicated for stroke prevention in atrial fibrillation and for the prevention and treatment of venous thromboembolism. As any anticoagulant, they are associated with a bleeding risk. Management of DOAC-induced bleeding is challenging. Idarucizumab, antidote for dabigatran, is currently available and is part of the therapeutic strategy, whereas antidotes for anti-Xa agents are under development. Activated or non-activated prothrombin concentrates are proposed, although their efficacy to reverse DOAC is uncertain. We propose an update on DOAC-associated bleeding management, integrating the availability of idarucizumab and the critical place of DOAC concentration measurements.
More Related Videos
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...